CLOBAZAM - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for clobazam and what is the scope of patent protection?
Clobazam
is the generic ingredient in three branded drugs marketed by Otter Pharms, Accord Hlthcare, Alkem Labs Ltd, Amneal, Aurobindo Pharma Ltd, Bionpharma, Chartwell Molecular, Hetero Labs Ltd Iii, Hikma, Lupin Ltd, Norvium Bioscience, Taro, Teva Pharms Usa, Upsher Smith Labs, Vistapharm, Lundbeck Pharms Llc, Amneal Pharms Co, Anda Repository, Apotex, Breckenridge, Micro Labs, MSN, Piramal, and Zydus Pharms, and is included in thirty-four NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Clobazam has one hundred and sixty-eight patent family members in nineteen countries.
There are ten drug master file entries for clobazam. Twenty-three suppliers are listed for this compound.
Summary for CLOBAZAM
International Patents: | 168 |
US Patents: | 3 |
Tradenames: | 3 |
Applicants: | 24 |
NDAs: | 34 |
Drug Master File Entries: | 10 |
Finished Product Suppliers / Packagers: | 23 |
Raw Ingredient (Bulk) Api Vendors: | 37 |
Clinical Trials: | 26 |
Patent Applications: | 6,022 |
Drug Prices: | Drug price trends for CLOBAZAM |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CLOBAZAM |
What excipients (inactive ingredients) are in CLOBAZAM? | CLOBAZAM excipients list |
DailyMed Link: | CLOBAZAM at DailyMed |
Recent Clinical Trials for CLOBAZAM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Dr Cipto Mangunkusumo General Hospital | Phase 4 |
Wayne State University | Phase 4 |
Jazz Pharmaceuticals | Phase 3 |
Pharmacology for CLOBAZAM
Drug Class | Benzodiazepine |
Mechanism of Action | Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inducers |
Anatomical Therapeutic Chemical (ATC) Classes for CLOBAZAM
US Patents and Regulatory Information for CLOBAZAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Accord Hlthcare | CLOBAZAM | clobazam | SUSPENSION;ORAL | 216008-001 | Sep 6, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hetero Labs Ltd Iii | CLOBAZAM | clobazam | TABLET;ORAL | 209795-001 | Oct 22, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Chartwell Molecular | CLOBAZAM | clobazam | TABLET;ORAL | 212092-002 | Oct 30, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Piramal | CLOBAZAM | clobazam | TABLET;ORAL | 209808-002 | Oct 22, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Lupin Ltd | CLOBAZAM | clobazam | TABLET;ORAL | 210545-002 | Dec 14, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Hetero Labs Ltd Iii | CLOBAZAM | clobazam | TABLET;ORAL | 209795-002 | Oct 22, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CLOBAZAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CLOBAZAM
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2735512 | ⤷ Sign Up | |
Japan | 2016513736 | 舌下及び頬用フィルム組成物 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 03012531 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2007030754 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2011143424 | ⤷ Sign Up | |
Austria | 553746 | ⤷ Sign Up | |
China | 1610851 | Package for electro-optical components | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.